Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase a localization

Cancer Immunology Research

Volumn 4, Issue 6, 2016, Pages 541-551

  Newick, Kheng ^a   O'brien, Shaun ^a   Sun, Jing ^a   Kapoor, Veena ^a   Maceyko, Steven ^a   Lo, Albert ^b   Puré, Ellen ^b   Moon, Edmund ^a   Albelda, Steven M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; CHIMERIC ANTIGEN RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; EZRIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; MESOTHELIN; PEPTIDE; PROSTAGLANDIN E2; REGULATORY SUBUNIT I ANCHORING DISRUPTOR PEPTIDE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL ADHESION; CELL CLONING; CELL KILLING; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; ENZYME INHIBITION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSGENE; TUMOR CELL; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CANCER TRANSPLANTATION; ENZYMOLOGY; FEMALE; IMMUNOLOGY; MESOTHELIOMA; METABOLISM; PROCEDURES; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL CULTURE;

ANIMALS; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MESOTHELIOMA; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84976552978     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0263     Document Type: Article

References (49)

1. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptormodified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365: 725-33.
2. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3: 95ra73.
3. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.N Engl J Med 2013;368:1509-18.
4. Gilham DE, Debets R, Pule M, Hawkins RE, Abken H. CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends Mol Med 2012; 18:377-84.
5. Lipowska-Bhalla G, Gilham DE, Hawkins RE, Rothwell DG. Targeted immunotherapy of cancer with CAR T cells: Achievements and challenges. Cancer Immunol Immunother 2012;61:953-62.
6. Gajewski TF.Failure at the effector phase:immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res 2007;13:5256-61.
7. Baitsch L, Fuertes-Marraco SA, Legat A, Meyer C, Speiser DE. The three main stumbling blocks for anticancer T cells. Trends Immunol 2012; 33:364-72.
8. Gajewski TF, Woo SR, Zha Y, Spaapen R, Zheng Y, Corrales L, et al. Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment. Curr Opin Immunol 2013;25:268-76.
9. Wang LC, Riese MJ, Moon EK, Albelda SM. Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road. Oncoimmunology 2013;2:e26492.
10. Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, et al. Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. Clin Cancer Res 2014;20:4262-73.
11. Gessi S, Merighi S, Sacchetto V, Simioni C, Borea PA. Adenosine receptors and cancer. Biochim Biophys Acta 2011;1808:1400-12.
12. Kirschner LS, Yin Z, Jones GN, Mahoney E. Mouse models of altered protein kinase A signaling. Endocr Relat Cancer 2009;16:773-93.
13. Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, et al. Tumorpromoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 2015;75:2800-10.
14. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2013;2:e26286.
15. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: Tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008;14:5947-52.
16. Carlos TM.Leukocyte recruitment at sites of tumor: dissonant orchestration. J Leukoc Biol 2001;70:171-84.
17. Lorenowicz MJ, Fernandez-Borja M, Hordijk PL. cAMP signaling in leukocyte transendothelial migration. Arterioscler Thromb Vasc Biol 2007;27: 1014-22.
18. Tasken K, Stokka AJ. The molecular machinery for cAMP-dependent immunomodulation in T-cells. Biochem Soc Trans 2006;34(Pt 4):476-9.
19. Mosenden R, Tasken K. Cyclic AMP-mediated immune regulation-overview of mechanisms of action in T cells. Cell Signal 2011;23:1009-16.
20. Brudvik KW, Tasken K. Modulation of T cell immune functions by the prostaglandin E(2)-cAMP pathway in chronic inflammatory states. Br J Pharmacol 2012;166:411-9.
21. Manz BN, Tan YX, Courtney AH, Rutaganira F, Palmer E, Shokat KM, et al. Small molecule inhibition of Csk alters affinity recognition by T cells. Elife 2015;4.
22. Clegg CH, Correll LA, Cadd GG, McKnight GS. Inhibition of intracellular cAMP-dependent protein kinase using mutant genes of the regulatory type I subunit. J Biol Chem 1987;262:13111-9.
23. Goldstein MD, Cochrane A, Watts TH. Cyclic-AMPmodulates downstream events in CD40-mediated signal transduction, but inhibition of protein kinase A has no direct effect on CD40 signaling. J Immunol 1997;159: 5871-80.
24. Raskovalova T, Lokshin A, Huang X, Su Y, Mandic M, Zarour HM, et al. Inhibition of cytokine production and cytotoxic activity of human antimelanoma specific CD8and CD4T lymphocytes by adenosine-protein kinase A type I signaling. Cancer Res 2007;67:5949-56.
25. Su Y, Huang X, Raskovalova T, Zacharia L, Lokshin A, Jackson E, et al. Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 2008;57:1611-23.
26. Su Y, Jackson EK, Gorelik E. Receptor desensitization and blockade of the suppressive effects of prostaglandin E(2) and adenosine on the cytotoxic activity of humanmelanoma-infiltrating T lymphocytes. Cancer Immunol Immunother 2011;60:111-22.
27. Murray AJ.Pharmacological PKA inhibition: All may not be what it seems. Sci Signal 2008;1:re4.
28. Beene DL, Scott JD. A-kinase anchoring proteins take shape. Curr Opin Cell Biol 2007;19:192-8.
29. Jarnaess E, Tasken K. Spatiotemporal control of cAMP signalling processes by anchored signalling complexes. Biochem Soc Trans 2007;35:931-7.
30. Ruppelt A, Mosenden R, Gronholm M, Aandahl EM, Tobin D, Carlson CR, et al. Inhibition of T cell activation by cyclic adenosine 50-monophosphate requires lipid raft targeting of protein kinase A type I by the A-kinase anchoring protein ezrin. J Immunol 2007;179:5159-68.
31. Carlson CR, Lygren B, Berge T, Hoshi N, Wong W, Tasken K, et al. Delineation of type I protein kinase A-selective signaling events using an RI anchoring disruptor. J Biol Chem 2006;281:21535-45.
32. Dell'Acqua ML, Smith KE, Gorski JA, Horne EA, Gibson ES, Gomez LL. Regulation of neuronal PKA signaling through AKAP targeting dynamics. Eur J Cell Biol 2006;85:627-33.
33. Mosenden R, Singh P, Cornez I, Heglind M, Ruppelt A, Moutschen M, et al. Mice with disrupted type I protein kinase A anchoring in T cells resist retrovirus-induced immunodeficiency. J Immunol 2011;186:5119-30.
34. Jarnaess E, Ruppelt A, Stokka AJ, Lygren B, Scott JD, Tasken K. Dual specificity A-kinase anchoring proteins (AKAPs) contain an additional binding region that enhances targeting of protein kinase A type I. J Biol Chem 2008;283:33708-18.
35. Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, et al. Enhanced effector responses in activated CD8 T cells deficient in diacylglycerol kinases. Cancer Res 2013;73:3566-77.
36. Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res 2014;2:154-66.
37. Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, et al. IL-2 intratumoral immunotherapy enhances CD8 T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J Immunol 2003;171:5051-63.
38. Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, et al. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptormediate regression of human disseminated tumor. Cancer Res 2010;70:9053-61.
39. Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin- specific chimeric antibody receptor. Clin Cancer Res 2011;17:4719-30.
40. Foster AE, Dotti G, Lu A, Khalil M, Brenner MK, Heslop HE, et al. Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor. J Immunother 2008;31:500-5.
41. Lacuesta K, Buza E, Hauser H, Granville L, Pule M, Corboy G, et al. Assessing the safety of cytotoxic T lymphocytes transduced with a dominant negative transforming growth factor-beta receptor. J Immunother 2006;29:250-60.
42. Wang L, Wen W, Yuan J, Helfand B, Li Y, Shi C, et al. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8 T cells. Clin Cancer Res 2010; 16:164-73.
43. Dannenberg AJ, Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 2003;4:431-6.
44. Sitkovsky MV, Lukashev D, Apasov S, Kojima H, Koshiba M, Caldwell C, et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu Rev Immunol 2004;22:657-82.
45. Brownlie RJ, Zamoyska R. T cell receptor signalling networks: Branched, diversified and bounded. Nat Rev Immunol 2013;13:257-69.
46. Oberprieler NG, Lemeer S, Kalland ME, Torgersen KM, Heck AJ, Tasken K. High-resolution mapping of prostaglandin E2-dependent signaling networks identifies a constitutively active PKA signaling node in CD8CD45RO T cells. Blood 2010;116:2253-65.
47. Moeller M, Haynes NM, Kershaw MH, Jackson JT, Teng MW, Street SE, et al. Adoptive transfer of gene-engineered CD4 helper T cells induces potent primary and secondary tumor rejection. Blood 2005;106:2995-3003.
48. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8() and CD4() subsets confer superior antitumor reactivity in vivo. Leukemia 2016;30:492-500.
49. Laudanna C, Campbell JJ, Butcher EC. Elevation of intracellular cAMP inhibits RhoA activation and integrin-dependent leukocyte adhesion induced by chemoattractants. J Biol Chem 1997;272:24141-4.